DelveInsight’s, “Diabetes Pipeline Insight 2024” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Diabetes Pipeline. Dive into DelveInsight’s comprehensive report today! @ Diabetes Pipeline Outlook
Key takeaways from the Diabetes Pipeline Report
- In October 2024:- Novo Nordisk A/S- This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.
- DelveInsight’s Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment.
- The leading Diabetes Companies such as Daewoong Tradipitant, Janssen Biotech,Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
- Promising Diabetes Therapies such as Aspirin, DA-2811, Forxiga, TG103, and others.
Stay ahead with the most recent pipeline outlook for Diabetes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Diabetes Treatment Drugs
Diabetes Emerging Drugs Profile
- Enavogliflozin – Daewoong
Enavogliflozin (DWP 16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor. The molecule is in phase-3 clinical trials for type-2 diabetic treatment. Enavogliflozin demonstrates the lowering of blood sugar and safety in diabetic patients in phase 2 clinical trials.
- Golimumab – Janssen Biotech
Golimumab is a human IgG1 monoclonal antibody, derived from immunizing genetically engineered mice with human TNFα. It inhibits soluble and transmembrane forms of TNF-α by binding to their specific receptors and blocking in consequence their bioactivity. It is currently under Phase II development for the treatment of Type 1 diabetes mellitus.
Explore groundbreaking therapies and clinical trials in the Diabetes Pipeline. Access DelveInsight’s detailed report now! @ New Diabetes Drugs
Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
Diabetes Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Unveil the future of Diabetes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Diabetes Market Drivers and Barriers
Scope of the Diabetes Pipeline Report
- Coverage- Global
- Diabetes Companies- Daewoong Tradipitant, Janssen Biotech,Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
- Diabetes Therapies- Aspirin, DA-2811, Forxiga, TG103, and others.
- Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Diabetes Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Diabetes Companies, Key Products and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- Diabetes: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Diabetes – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Diabetes companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Diabetes Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Enavogliflozin: Daewoong
- Product Description
- Research and Development
- Product Development Activities
- Mid Stage Products (Phase II)
- Comparative Analysis
- Golimumab: Janssen Biotech
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase II/I)
- Comparative Analysis
- IMCY-0098: ImCyse
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- ENT-001: Enthera
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Diabetes Key Companies
- Diabetes Key Products
- Diabetes- Unmet Needs
- Diabetes- Market Drivers and Barriers
- Diabetes- Future Perspectives and Conclusion
- Diabetes Analyst Views
- Diabetes Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/